- Home
- JANX vs INDV Comparison
JANX vs INDV Comparison
Compare JANX & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- INDV
- Stock Information
- Founded
- JANX 2017
- INDV 1994
- Country
- JANX United States
- INDV United States
- Employees
- JANX N/A
- INDV N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- INDV Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- INDV Health Care
- Exchange
- JANX Nasdaq
- INDV Nasdaq
- Market Cap
- JANX 1.6B
- INDV 1.4B
- IPO Year
- JANX 2021
- INDV N/A
- Fundamental
- Price
- JANX $23.60
- INDV $14.01
- Analyst Decision
- JANX Strong Buy
- INDV Strong Buy
- Analyst Count
- JANX 7
- INDV 2
- Target Price
- JANX $94.29
- INDV $14.50
- AVG Volume (30 Days)
- JANX 808.2K
- INDV 1.3M
- Earning Date
- JANX 08-06-2025
- INDV 07-24-2025
- Dividend Yield
- JANX N/A
- INDV N/A
- EPS Growth
- JANX N/A
- INDV N/A
- EPS
- JANX N/A
- INDV N/A
- Revenue
- JANX $9,336,000.00
- INDV $1,170,000,000.00
- Revenue This Year
- JANX N/A
- INDV N/A
- Revenue Next Year
- JANX $1,470.82
- INDV $3.00
- P/E Ratio
- JANX N/A
- INDV N/A
- Revenue Growth
- JANX 28.12
- INDV 4.09
- 52 Week Low
- JANX $22.48
- INDV $7.33
- 52 Week High
- JANX $71.71
- INDV $16.98
- Technical
- Relative Strength Index (RSI)
- JANX 41.60
- INDV 65.85
- Support Level
- JANX $24.45
- INDV $13.69
- Resistance Level
- JANX $27.28
- INDV $14.23
- Average True Range (ATR)
- JANX 1.35
- INDV 0.54
- MACD
- JANX -0.09
- INDV -0.01
- Stochastic Oscillator
- JANX 22.20
- INDV 78.80
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.